Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas.

Reviewer: Tracy d'Entremont, MD
OncoLink
Ultima Vez Modificado: 1 de junio del 2003

Translation for this article does not exist

Blogs

The Power of a Cancer Support Group
by Bob Riter
May 26, 2016